Turning Precision Medicine into Action.



CerbACT Asia empowers precision medicine development and drives better patient outcomes by applying deep biomarker expertise to research 8 clinical development strategies. We are enabled by cutting edge technologies in Flow Cytometry (FCM), Immunohistochemistry (IHC), and PBMC/cell isolations, while functioning as a central laboratory in the APAC region. Working with biotech, pharma, government and non-governmental organizations, our team is ready to turn precision medicine into action!

CerbACT Asia - Center of Immuno-Oncology's Areas of Expertise are...

01 Central Lab

CerbACT Asia is part of the **global Cerba Research network**, and it serves as a central lab in the Asia-Pacific region with full logistics support and storage.

Q2 Flow Cytometry

With a focus on immunophenotyping, CerbACT Asia will make use of Flow Cytometry to support drug developers in the I/O industry. The Taipei laboratory is equipped with 2 IVD-grade Becton Dickinson FACSLyric flow cytometers, measuring 12 channels per instrument.

03 Immunohistochemistry

IHC helps to **understand biomarker expression** in the tumor microenvironment and hence gives insights for personalizing patients's therapies. CerbACT Asia **focuses on PD-L1 CDx as well as other exploratory IHC staining**, and the center offers testing using the IVD-grade Ventana BenchMark Ultra platform.

4 Peripheral Blood Mononuclear Cells

Isolated PBMCs yield the best response if it is **processed promptly after collection**. The CerbACT Asia facility in Taipei offers PBMC and other cell isolation in a **geographically advantageous location**, and this service is supported by the Muse Cell Analyzer, Countess 3 Cell Counter, and GentleMACS Tissue Dissociator for overall processing.



Learn more about CerbACT Asia: www.cerbaresearch.com www.actgenomics.com

